Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

1.

Prospective cross-sectional study on faecal immunochemical tests: sex specific cut-off values to obtain equal sensitivity for colorectal cancer?

van Turenhout ST, Oort FA, van der Hulst RW, Visscher AP, Terhaar sive Droste JS, Scholten P, Bouman AA, Meijer GA, Mulder CJ, van Rossum LG, Coupé VM.

BMC Gastroenterol. 2014 Dec 21;14:217. doi: 10.1186/s12876-014-0217-7.

2.

Electronic nose can discriminate colorectal carcinoma and advanced adenomas by fecal volatile biomarker analysis: proof of principle study.

de Meij TG, Larbi IB, van der Schee MP, Lentferink YE, Paff T, Terhaar Sive Droste JS, Mulder CJ, van Bodegraven AA, de Boer NK.

Int J Cancer. 2014 Mar 1;134(5):1132-8. doi: 10.1002/ijc.28446. Epub 2013 Sep 2.

PMID:
23959518
3.

Similar fecal immunochemical test results in screening and referral colorectal cancer.

van Turenhout ST, van Rossum LG, Oort FA, Laheij RJ, van Rijn AF, Terhaar sive Droste JS, Fockens P, van der Hulst RW, Bouman AA, Jansen JB, Meijer GA, Dekker E, Mulder CJ.

World J Gastroenterol. 2012 Oct 14;18(38):5397-403. doi: 10.3748/wjg.v18.i38.5397.

4.

Faecal immunochemical test accuracy in patients referred for surveillance colonoscopy: a multi-centre cohort study.

Terhaar sive Droste JS, van Turenhout ST, Oort FA, van der Hulst RW, Steeman VA, Coblijn U, van der Eem L, Duijkers R, Bouman AA, Meijer GA, Depla AC, Scholten P, Loffeld RJ, Coupé VM, Mulder CJ.

BMC Gastroenterol. 2012 Jul 24;12:94. doi: 10.1186/1471-230X-12-94.

5.

Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection.

Bosch LJ, Mongera S, Terhaar Sive Droste JS, Oort FA, van Turenhout ST, Penning MT, Louwagie J, Mulder CJ, van Engeland M, Carvalho B, Meijer GA.

Cell Oncol (Dordr). 2012 Aug;35(4):309-15. doi: 10.1007/s13402-012-0092-6. Epub 2012 Jul 21.

PMID:
22821210
6.

Hemorrhoids detected at colonoscopy: an infrequent cause of false-positive fecal immunochemical test results.

van Turenhout ST, Oort FA, Terhaar sive Droste JS, Coupé VM, van der Hulst RW, Loffeld RJ, Scholten P, Depla AC, Bouman AA, Meijer GA, Mulder CJ, van Rossum LG.

Gastrointest Endosc. 2012 Jul;76(1):136-43. doi: 10.1016/j.gie.2012.03.169.

PMID:
22726472
7.

Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer.

Fijneman RJ, de Wit M, Pourghiasian M, Piersma SR, Pham TV, Warmoes MO, Lavaei M, Piso C, Smit F, Delis-van Diemen PM, van Turenhout ST, Terhaar sive Droste JS, Mulder CJ, Blankenstein MA, Robanus-Maandag EC, Smits R, Fodde R, van Hinsbergh VW, Meijer GA, Jimenez CR.

Clin Cancer Res. 2012 May 1;18(9):2613-24. doi: 10.1158/1078-0432.CCR-11-1937. Epub 2012 Feb 20.

8.

Anticipating implementation of colorectal cancer screening in The Netherlands: a nation wide survey on endoscopic supply and demand.

van Turenhout ST, Terhaar sive Droste JS, Meijer GA, Masclée AA, Mulder CJ.

BMC Cancer. 2012 Jan 26;12:46. doi: 10.1186/1471-2407-12-46.

9.

Ischemic colitis with diverticular sparing.

Terhaar sive Droste JS, Van Weyenberg SJ.

Gastrointest Endosc. 2012 Feb;75(2):424; discussion 424. doi: 10.1016/j.gie.2011.10.003. Epub 2011 Dec 9. No abstract available.

PMID:
22168995
10.

DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT.

Bosch LJ, Oort FA, Neerincx M, Khalid-de Bakker CA, Terhaar sive Droste JS, Melotte V, Jonkers DM, Masclee AA, Mongera S, Grooteclaes M, Louwagie J, van Criekinge W, Coupé VM, Mulder CJ, van Engeland M, Carvalho B, Meijer GA.

Cancer Prev Res (Phila). 2012 Mar;5(3):464-72. doi: 10.1158/1940-6207.CAPR-11-0315. Epub 2011 Dec 1.

11.

Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: a colonoscopy controlled prospective cohort study.

Oort FA, van Turenhout ST, Coupé VM, van der Hulst RW, Wesdorp EI, Terhaar sive Droste JS, Larbi IB, Kanis SL, van Hengel E, Bouman AA, Meijer GA, Mulder CJ.

BMC Cancer. 2011 Oct 10;11:434. doi: 10.1186/1471-2407-11-434.

12.

Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers.

Terhaar sive Droste JS, Oort FA, van der Hulst RW, van Heukelem HA, Loffeld RJ, van Turenhout ST, Ben Larbi I, Kanis SL, Neerincx M, Räkers M, Coupé VM, Bouman AA, Meijer GA, Mulder CJ.

Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):272-80. doi: 10.1158/1055-9965.EPI-10-0848. Epub 2010 Dec 6.

13.

Colonic work-up after incomplete colonoscopy: significant new findings during follow-up.

Neerincx M, Terhaar sive Droste JS, Mulder CJ, Räkers M, Bartelsman JF, Loffeld RJ, Tuynman HA, Brohet RM, van der Hulst RW.

Endoscopy. 2010 Sep;42(9):730-5. doi: 10.1055/s-0030-1255523. Epub 2010 Jul 28.

PMID:
20669092
14.

Does delay in diagnosing colorectal cancer in symptomatic patients affect tumor stage and survival? A population-based observational study.

Terhaar sive Droste JS, Oort FA, van der Hulst RW, Coupé VM, Craanen ME, Meijer GA, Morsink LM, Visser O, van Wanrooij RL, Mulder CJ.

BMC Cancer. 2010 Jun 28;10:332. doi: 10.1186/1471-2407-10-332.

15.

[Diagnosis of colorectal tumours in daily clinical practice: comparison of colonoscopy and sigmoidoscopy].

Terhaar sive Droste JS, van Wanrooij RL, Morsink LM, van der Hulst RW, Craanen ME, Bartelsman JW, Meijer GA, Mulder CJ.

Ned Tijdschr Geneeskd. 2009;153:A731. Dutch.

PMID:
20003556
16.

Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test.

Oort FA, Terhaar Sive Droste JS, Van Der Hulst RW, Van Heukelem HA, Loffeld RJ, Wesdorp IC, Van Wanrooij RL, De Baaij L, Mutsaers ER, van der Reijt S, Coupe VM, Berkhof J, Bouman AA, Meijer GA, Mulder CJ.

Aliment Pharmacol Ther. 2010 Feb 1;31(3):432-9. doi: 10.1111/j.1365-2036.2009.04184.x. Epub 2009 Oct 29.

17.

MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression.

Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, Mongera S, Postma C, Meijerink WJ, Carvalho B, Meijer GA.

Br J Cancer. 2009 Aug 18;101(4):707-14. doi: 10.1038/sj.bjc.6605037.

18.

Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer.

Kim MS, Louwagie J, Carvalho B, Terhaar Sive Droste JS, Park HL, Chae YK, Yamashita K, Liu J, Ostrow KL, Ling S, Guerrero-Preston R, Demokan S, Yalniz Z, Dalay N, Meijer GA, Van Criekinge W, Sidransky D.

PLoS One. 2009 Aug 7;4(8):e6555. doi: 10.1371/journal.pone.0006555.

19.

Colonoscopic yield of colorectal neoplasia in daily clinical practice.

Terhaar Sive Droste JS, Craanen ME, van der Hulst RW, Bartelsman JF, Bezemer DP, Cappendijk KR, Meijer GA, Morsink LM, Snel P, Tuynman HA, van Wanrooy RL, Wesdorp EI, Mulder CJ.

World J Gastroenterol. 2009 Mar 7;15(9):1085-92.

20.

Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression.

Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, van de Wiel MA, van Criekinge W, Thas O, Matthäi A, Cuesta MA, Terhaar Sive Droste JS, Craanen M, Schröck E, Ylstra B, Meijer GA.

Gut. 2009 Jan;58(1):79-89. doi: 10.1136/gut.2007.143065. Epub 2008 Oct 1.

PMID:
18829976
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk